Lalan S. Wilfong

Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b–based chemoradiation: ACOSOG Trial Z05031

Vincent J. Picozzi, Ross A. Abrams, Paul A. Decker et al. · Annals of Oncology · 2010 · 104 citations · Full text

Surgical Oncology, Pancreatic Cancer, Gastrointestinal Oncology +9

Implementation of Electronic Patient-Reported Outcomes for Symptom Monitoring in a Large Multisite Community Oncology Practice: Dancing the Texas Two-Step Through a Pandemic

Debra A. Patt, Lalan S. Wilfong, Kathryn Elizabeth Hudson et al. · JCO Clinical Cancer Informatics · 2021 · 80 citations · Full text

Telemedicine in Community Cancer Care: How Technology Helps Patients With Cancer Navigate a Pandemic

Debra A. Patt, Lalan S. Wilfong, Sára Tóth et al. · JCO Oncology Practice · 2021 · 59 citations · Full text

Family Medicine, Remote Patient Monitoring, Rural Areas +20

Adding Patient-Reported Outcomes to Medicare’s Oncology Value-Based Payment Model

Ethan Basch, Lalan S. Wilfong, Deborah Schrag · JAMA · 2020 · 53 citations

Patient-reported Outcomes, Otorhinolaryngology, Surgery +19

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

Donald Richards, Paul R. Kuefler, Carlos Becerra et al. · Investigational New Drugs · 2009 · 48 citations

Urology, Oncology, Phase Ii +9